Pacer Advisors Inc. Sells 447,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Pacer Advisors Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 17.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,142,491 shares of the specialty pharmaceutical company’s stock after selling 447,157 shares during the quarter. Pacer Advisors Inc. owned 6.64% of Collegium Pharmaceutical worth $61,382,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its position in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. Foundry Partners LLC raised its position in Collegium Pharmaceutical by 3.3% in the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock worth $610,000 after purchasing an additional 509 shares during the period. CWM LLC lifted its stake in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares during the period.

Collegium Pharmaceutical Trading Up 4.1 %

NASDAQ COLL opened at $33.91 on Tuesday. Collegium Pharmaceutical, Inc. has a one year low of $28.39 and a one year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 14.62 and a beta of 0.82. The company’s 50-day simple moving average is $30.74 and its two-hundred day simple moving average is $34.15.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on COLL shares. Piper Sandler reissued a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.